Satellos Bioscience Inc., a biotechnology company based in Toronto, Canada, is making significant strides in the healthcare sector with its focus on skeletal muscle regeneration. The company is listed on the Toronto Stock Exchange and operates within the biotechnology industry. As of July 9, 2026, the close price of Satellos Bioscience Inc. was CAD 13.53, with a market capitalization of CAD 276,638,208. The company’s stock has experienced fluctuations over the past year, reaching a 52-week high of CAD 18.98 on March 2, 2026, and a low of CAD 6.36 on August 12, 2025. The price-to-earnings ratio stands at -4.95, reflecting the company’s current financial metrics.
Satellos Bioscience Inc. is dedicated to revolutionizing the treatment of severe muscle disorders by developing medicines that enhance the body’s natural self-repair mechanisms. This innovative approach is particularly focused on addressing Duchenne muscular dystrophy (DMD), a severe muscle-wasting disease. The company recently reported promising interim results from its Phase 2 study of the oral compound SAT‑3247, designed specifically for DMD.
Over a six-month period, the study involved four participants who were administered SAT‑3247. The results indicated a modest reduction in muscle fat content and an improvement in upper-limb strength among the treated individuals. Importantly, the safety profile of the compound remained consistent with earlier observations, underscoring its potential as a viable treatment option. These findings represent a positive development in Satellos Bioscience Inc.’s ongoing efforts to advance therapeutic solutions for Duchenne muscular dystrophy.
The company’s commitment to innovation and its focus on addressing critical healthcare challenges position it as a noteworthy player in the biotechnology sector. For more detailed information about Satellos Bioscience Inc.’s work and mission, interested parties can visit their website at www.satellos.com .
